Bristol-Myers Squibb is buying rival Celgene in a cash and stock deal valued at about US$74 billion or US$90 billion including debt.
The tie-up, which is subject to various approvals, is expected to be completed in the second half of 2019, will unite their portfolios of cancer-fighting drugs.
The combined company could become the fourth largest pharmaceutical firm in the United States. Together they have nine different drugs—six from Bristol-Myers and three from Celgene—with global sales of more than US$1 billion each, led by US$8.2 billion in sales for Revlimid, the Celgene drug used to treat multiple myeloma, a cancer that affects bone marrow and white blood cells.
The companies also announced they have six other drugs under development which could debut over the next 12 to 24 months, representing more than US$15 billion in potential annual revenue.
Full Content: CNN
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
T-Mobile’s Acquisition of Ka’ena Corporation Receives FCC Approval
Apr 26, 2024 by
CPI
UK Regulator Announces Two New Senior Executive Appointments
Apr 26, 2024 by
CPI
Paramount Global and Skydance Media Near Merger Deal, Eyeing CEO Change
Apr 26, 2024 by
CPI
BHP Unveils £31bn Mining Megamerger Proposal with Anglo American
Apr 25, 2024 by
nhoch@pymnts.com
ByteDance Prefers Shutdown Over Sale of TikTok Amid US Ban Threats
Apr 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI